Stay updated on Pembrolizumab and Chemo in Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Chemo in Bladder Cancer Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2Fn4G-AxN927SiQOuw_u5JNJsKdj8.uncropped.jpg&w=3840&q=75)
Latest updates to the Pembrolizumab and Chemo in Bladder Cancer Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check4 days agoChange DetectedThe website has been updated to version v2.10.0, adding 2 more interventions/treatments, 5 more study numbers, and noting that the study now has 175 locations.SummaryDifference0.3%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.0%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.0%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content.SummaryDifference0.0%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent change in the webpage content.SummaryDifference0.0%
- Check32 days agoChange DetectedThe value 'Show more Revision: v2.9.0' has been updated to 'MedlinePlus Genetics related topics: Bladder cancer MedlinePlus related topics: Bladder Cancer Drug Information available for: Cisplatin Gemcitabine Pembrolizumab FDA Drug and Device Resources'. This change reflects an update in the information provided on the webpage.SummaryDifference40%
Stay in the know with updates to Pembrolizumab and Chemo in Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Chemo in Bladder Cancer Clinical Trial page.